Agenus(AGEN) - 2025 Q4 - Annual Results

Revenue and Financial Performance - Agenus recognized approximately $4.2 million in net revenue from early access programs in 2025, with $3.2 million in the fourth quarter alone[18]. - The company reported an operating loss of $20.2 million for the full year 2025[18]. Clinical Trials and Research - The BOT+BAL program achieved a 42% two-year overall survival rate and a median overall survival of approximately 21 months in heavily pretreated MSS mCRC patients[11]. - The BATTMAN Phase 3 registrational trial for BOT+BAL has been initiated, aiming to enroll approximately 830 patients across more than 100 sites in multiple countries[15][21]. - Clinical data from over 1,200 patients across nine tumor types support the potential of BOT+BAL as a next-generation immunotherapy[10][28]. Strategic Collaborations and Partnerships - A strategic collaboration with Zydus Lifesciences provided $91 million in upfront capital to strengthen Agenus' balance sheet and manufacturing capacity[16]. - The collaboration with Zydus includes a $20 million contingent payment triggered by initial BOT+BAL work orders[17]. Program Expansion and Global Reach - The early access programs have expanded globally, with over 200 physician inquiries from more than 30 countries[5][9]. - France's AAC program has expanded to include additional cancers, enhancing patient access to BOT+BAL[7]. Regulatory and Commercial Strategy - Agenus aims to advance regulatory filings in the U.S. and EU while strengthening its commercial readiness[23].